| Protein Name | Neurofilament Heavy Chain (NF-H) |
|---|
| Gene | [NEFH](/genes/NEFH) |
|---|
| UniProt ID | [P12036](https://www.uniprot.org/uniprot/P12036) |
|---|
| PDB Structure | 1G3C, 2N3P |
|---|
| Molecular Weight | 200 kDa (1,026 amino acids) |
|---|
| Subcellular Localization | Axons, neuronal cytoskeleton |
|---|
| Protein Family | Intermediate filament family |
|---|
Nefh Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Neurofilament Heavy Chain (NEFH) is the heaviest subunit of the neurofilament intermediate filament family, which also includes NEFL (light) and NEFM (medium) subunits. Neurofilaments are essential structural proteins that maintain axonal caliber, facilitate rapid axonal transport, and provide structural stability to large myelinated axons. NEFH is particularly important in large-diameter motor and sensory neurons, where it constitutes up to 50% of the total neurofilament protein content.
NEFH is the heaviest neurofilament subunit with unique structural features:
- Alpha-helical rod domain (aa 150-420): Central coiled-coil region that mediates dimerization and filament assembly
- Lysine-serine-proline (KSP) repeats: Over 50 potential phosphorylation sites in the tail domain
- C-terminal tail domain: Long projections (~450 aa) with multiple phosphorylation sites creating side-arm projections
The KSP repeat domain is heavily phosphorylated:
- Phosphorylation occurs primarily on serine residues within KSP motifs
- Creates negative charges that regulate interfilament spacing
- Controls binding to microtubule-based motors
- Hyperphosphorylation is a pathological feature in some diseases
- Axonal scaffold: Provides structural integrity to large myelinated axons
- Caliber determinant: Regulates axonal diameter through phosphorylation state
- Transport modulator: Phosphorylation controls binding to kinesin/dynein motors
- Myelination coordinator: Coordinates with myelinating oligodendrocytes and Schwann cells
| Phosphorylation State |
Effect |
| Unphosphorylated |
Axonal transport, assembly |
| Phosphorylated |
Increased caliber, reduced transport |
NEFH is critically involved in ALS pathogenesis:
- Disrupted filament assembly: Mutations in NEFH impair proper neurofilament assembly
- Impaired axonal transport: Defective transport leads to axonal dysfunction
- Aggregation in inclusion bodies: NEFH-positive aggregates found in motor neurons
- Biomarker: NEFH fragments in CSF and blood correlate with disease progression
NEFH mutations cause:
- Distal axon degeneration
- Reduced nerve conduction velocity
- Secondary demyelination
- Axonal loss in peripheral nerves
- NEFH accumulates in neurofibrillary tangles
- Cross-linking with tau protein
- Axonal transport deficits
- Reduced NEFH expression in dopaminergic neurons
- Axonal pathology in substantia nigra
NEFH and its fragments serve as important biomarkers:
| Application |
Fluid |
Significance |
| ALS diagnosis |
CSF |
Elevated NEFH |
| Disease progression |
Blood/CSF |
Correlates with progression rate |
| Treatment response |
CSF/Blood |
NEFH change predicts outcome |
| CMT assessment |
Serum |
Axonal loss indicator |
- Diagnostic specificity: High in ALS vs. mimics
- Prognostic value: Higher levels = faster progression
- Therapeutic monitoring: Treatment response reflected in levels
- Motor cortex: High expression in pyramidal neurons
- Spinal cord: Abundant in anterior horn cells
- Peripheral nerves: Large-diameter sensory and motor neurons
- Expression increases postnatally
- Correlates with myelination
- Maintained throughout adult life
- NEFH overexpression: Motor neuron degeneration
- NEFH knockout: Reduced axonal caliber
- Phosphorylation mutants: Transport defects
- Phosphorylation modulators: Affect neurofilament transport
- Aggregation inhibitors: Prevent toxic aggregation
- Axonal transport enhancers: Restore function
- Neurofilament levels as outcome measures
- Monitoring treatment response
- Lee MK, et al. (1995). The neurofilament heavy subunit is required for neurofilament assembly. J Cell Biol.
- Julien JP, et al. (1999). Neurofilament functions in health and disease. Biochim Biophys Acta.
- Friedreich A, et al. (2015). Neurofilament light chain and heavy chain as biomarkers in ALS. Ann Neurol.
- Xu Z, et al. (2013). Phosphorylation of neurofilament heavy chain regulates axonal transport. J Neurochem.
- Perrot R, et al. (2008). Neurofilaments in health and disease. Prog Neurobiol.
Nefh Protein plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Nefh Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Lee MK, et al. (1995). The neurofilament heavy subunit is required for neurofilament assembly. J Cell Biol. PMID:7615644
- Julien JP, et al. (1999). Neurofilament functions in health and disease. Biochim Biophys Acta. PMID:9920427
- Friedreich A, et al. (2015). Neurofilament light chain and heavy chain as biomarkers in ALS. Ann Neurol. PMID:25940586
- Xu Z, et al. (2013). Phosphorylation of neurofilament heavy chain regulates axonal transport. J Neurochem. PMID:24028532
- Perrot R, et al. (2008). Neurofilaments in health and disease. Prog Neurobiol. PMID:18804014
- Nixon RA, et al. (1993). The role of neurofilaments in axonal transport. J Neurosci Res. PMID:8385673
- Lee JC, et al. (2018). Neurofilament biomarkers in ALS. J Neurol Neurosurg Psychiatry. PMID:29643113
- Lu CH, et al. (2017). Neurofilament light chain: a prognostic biomarker in ALS. Neurology. PMID:28663219